The Controlled Substances Board is created in Wis. Stat. § 15.405(5g) and has authority as outlined in Wis. Stat. ch. 961.
The members of the Controlled Substances Board are appointed as outlined in Wis. Stat. § 15.405(5g). The Board consists of 7 members with no term expiration dates: the Attorney General, the Secretary of Health Services, and the Secretary of Agriculture, Trade and Consumer Protection, or their designees; the chairperson of the Pharmacy Examining Board, the chairperson of the Medical Examining Board, the chairperson of the Dentistry Examining Board, and the chairperson of the Board of Nursing, or a designee; and 2 members appointed by the Governor to serve 3-year terms: 1 psychiatrist member and 1 pharmacologist member.
|Member||Officer||Member Type||Term Expiration|
|Englebert, Doug||Chairperson||DHS Designated Member||N/A|
|Bloom, Alan||Vice Chairperson||Pharmacologist||5/1/2020|
|Bellay, Yvonne M.||Secretary||DATCP Designated Member||N/A|
|Huck, Leonardo||Dentistry Board Representative||N/A|
|Smith Houskamp, Elizabeth||Board of Nursing Representative||N/A|
|Trapskin, Philip||Pharmacy Board Representative||N/A|
|Virgil, Tina||Attorney General Designee||N/A|
|Westlake, Timothy||Medical Board Representative||N/A|
*Board members whose terms have expired may continue to serve until their successor is confirmed by the Senate.
On April 1, 2017, an emergency rule amending
ch. CSB 4 went into effect. This emergency rule revises requirements for the Prescription Drug Monitoring Program.
2013 Wisconsin Act 267, also known as Lydia's Law, charges the Controlled Substances Board with aiding a physician in applying for and processing an investigational drug permit for use of cannabidoil (CBD oil) as treatment for a seizure disorder.
Investigational Drug Permit For Cannabidoil
Last updated: 2/18/2019